Case Study: Leading Biotech Company achieves over 90% eCOA adherence and rapid 900-participant enrollment with Medable

Medable enables >90% eCOA adherence in vaccine trial

Leading Biotech Company engaged Medable to run a vaccine trial using eCOA+, ePRO and the Medable platform. The sponsor’s challenge was to collect consistent reactogenicity diary data from a participant population aged 50+, achieve ≥90% adherence, and rapidly enroll 900 participants within 30 days despite concerns that older participants might be reluctant to use digital trial technology.

Medable implemented a user-friendly workflow with BYOD or provisioned devices, intuitive question wording, automated reminders, site notifications, real-time data access, TeleVisit support, and a two-part onboarding designed with its Patient Caregiver Network; Total Consent eConsent and robust reporting supported fast enrollment. As a result, Medable helped the study achieve over 90% eCOA adherence, enroll 900 participants in under a month, and split device use roughly 50/50 between provisioned and BYOD, enabling timely interventions and sustained engagement.